WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318880
CAS#: 64461-82-1 (HCl)
Description: Tizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, ALS, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant. It is also prescribed for some symptoms of fibromyalgia.
Hodoodo Cat#: H318880
Name: Tizanidine HCl
CAS#: 64461-82-1 (HCl)
Chemical Formula: C9H9Cl2N5S
Exact Mass: 0.00
Molecular Weight: 290.166
Elemental Analysis: C, 37.25; H, 3.13; Cl, 24.43; N, 24.14; S, 11.05
Related CAS #: 51322-75-9 (free base) 64461-82-1 (HCl) 106314-85-6 (lactate)
Synonym: BRN0618691; BRN-0618691; BRN 0618691; AB 021 ; AN 021; DS 103-282; Tizanidine; Tizanidine hydrochloride; Sirdalud; Ternelin.
IUPAC/Chemical Name: 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole monohydrochloride
InChi Key: ZWUKMNZJRDGCTQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H8ClN5S.ClH/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9;/h1-2H,3-4H2,(H2,11,12,13);1H
SMILES Code: ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 290.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Karol DE, Muzyk AJ, Preud'homme XA. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. Gen Hosp Psychiatry. 2011 Jan-Feb;33(1):84.e1-2. doi: 10.1016/j.genhosppsych.2010.10.003. Epub 2010 Nov 13. Review. PubMed PMID: 21353141.
2: Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008 Aug;9(12):2209-15. doi: 10.1517/14656566.9.12.2209 . Review. PubMed PMID: 18671474.
3: Henney HR 3rd, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract. 2008 Feb;62(2):314-24. doi: 10.1111/j.1742-1241.2007.01660.x. Review. PubMed PMID: 18199279.
4: Kamen L, Henney HR 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008 Feb;24(2):425-39. doi: 10.1185/030079908X261113 . Review. PubMed PMID: 18167175.
5: Smith HS, Barton AE. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. Am J Hosp Palliat Care. 2000 Jan-Feb;17(1):50-8. Review. PubMed PMID: 11094920.
6: Afonso Pérez E, Pego Reigosa R, Lancho Seco A, Brañas Fernández F. [Tizanidine-induced toxic hepatitis]. Med Clin (Barc). 1999 Apr 10;112(12):478-9. Review. Spanish. PubMed PMID: 10320966.
7: Brenner R, Hyman N, Knobler R, O'Brien M, Stephan T. An approach to switching patients from baclofen to tizanidine. Hosp Med. 1998 Oct;59(10):778-82. Review. PubMed PMID: 9850294.
8: Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. Review. PubMed PMID: 9074844.
9: Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994 Nov;44(11 Suppl 9):S6-10; discussion S10-1. Review. PubMed PMID: 7970012.
10: Roberts RC, Part NJ, Pokorny R, Muir C, Leslie GC, Emre M. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology. 1994 Nov;44(11 Suppl 9):S29-31. Review. PubMed PMID: 7970008.
11: Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity. Neurology. 1994 Nov;44(11 Suppl 9):S21-7; discussion S27-8. Review. PubMed PMID: 7970007.
12: Hutchinson DR. Modified release tizanidine: a review. J Int Med Res. 1989 Nov-Dec;17(6):565-73. Review. Erratum in: J Int Med Res 1990 Jan-Feb;18(1):preceding 1. PubMed PMID: 2697626.
